skip to context

Adis launches new open access pharmacoeconomics journal

PharmacoEconomics - Open will provide readers with the latest on health economics and outcomes

Heidelberg | Auckland, 1 August 2016

Journal cover: PharmacoEconomics - OpenAdis, a leading global provider of drug information, is launching a new open access pharmacoeconomics journal, which will be added to their portfolio in 2017. Called PharmacoEconomics - Open, the new journal will focus on cost and health outcomes associated with drugs, devices and other healthcare interventions. PharmacoEconomics - Open has the same co-editors as Adis’s flagship subscription journal in the field, PharmacoEconomics. With 30 years of professional publishing experience between them, the co-editors will ensure that this new journal becomes an essential source of information.

Co-Editor Christopher Carswell at Adis says, “I am delighted to be part of the editorial team of PharmacoEconomics - Open. There is an ever-increasing need to provide credible open access journals to help researchers disseminate their work. PharmacoEconomics - Open provides such a venue for the health economics and outcomes research community. It will allow researchers to maximize the reach of their work not only within the research community but also amongst the most important stakeholder of all – the patient.”

Co-Editor Timothy Wrightson, also at Adis, adds, “We are excited to be providing this new publication which offers much-needed economic analyses and health outcomes research. This continues to be a rapidly growing field and is increasingly important as health budgets struggle to keep pace with medical innovations and population healthcare needs. Decision makers need access to these studies to inform optimal healthcare policy and practice.”

The new journal will be published under the AdisOpen program meaning that it will appear online only and will be entirely open access. This will make it accessible to readers globally without the need for a subscription. All articles published in the journal will undergo rigorous peer review to ensure that they meet the high standards expected from Adis.

Adis has more than 40 years’ experience in publishing, with a portfolio of more than 30 medical journals and newsletters. As part of Springer Nature, they are able to offer many benefits to authors including efficient article submission, tracking and review, expedited publication timelines, and high visibility through Springer Nature’s proprietary content platforms. Visit

Springer Nature is a leading global research, educational and professional publisher, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher, publisher of the world’s most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. Visit and follow @SpringerNature.

Further Information

About the journal PharmacoEconomics - Open

Follow PharmacoEconomics - Open on Twitter


Joan Robinson | Springer Nature | Communications

tel +49 6221 487 8130 |